Literature DB >> 17615175

Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.

Robert C De Lisle1, Eileen Roach, Kyle Jansson.   

Abstract

The accumulation of mucus in affected organs is characteristic of cystic fibrosis (CF). The CF mouse small intestine has dramatic mucus accumulation and exhibits slower interdigestive intestinal transit. These factors are proposed to play cooperative roles that foster small intestinal bacterial overgrowth (SIBO) and contribute to the innate immune response of the CF intestine. It was hypothesized that decreasing the mucus accumulation would reduce SIBO and might improve other aspects of the CF intestinal phenotype. To test this, solid chow-fed CF mice were treated with an osmotic laxative to improve gut hydration or liquid-fed mice were treated orally with N-acetylcysteine (NAC) to break mucin disulfide bonds. Treatment with laxative or NAC reduced mucus accumulation by 43% and 50%, respectively, as measured histologically as dilation of the intestinal crypts. Laxative and NAC also reduced bacterial overgrowth in the CF intestine by 92% and 63%, respectively. Treatment with laxative normalized small intestinal transit in CF mice, whereas NAC did not. The expression of innate immune response-related genes was significantly reduced in laxative-treated CF mice, whereas there was no significant effect in NAC-treated CF mice. In summary, laxative and NAC treatments of CF mice reduced mucus accumulation to a similar extent, but laxative was more effective than NAC at reducing bacterial load. Eradication of bacterial overgrowth by laxative treatment was associated with normalized intestinal transit and a reduction in the innate immune response. These results suggest that both mucus accumulation and slowed interdigestive small intestinal transit contribute to SIBO in the CF intestine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615175     DOI: 10.1152/ajpgi.00195.2007

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  35 in total

1.  Impact of Eimeria tenella Coinfection on Campylobacter jejuni Colonization of the Chicken.

Authors:  Sarah E Macdonald; Pauline M van Diemen; Henny Martineau; Mark P Stevens; Fiona M Tomley; Richard A Stabler; Damer P Blake
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 2.  Redox biology of the intestine.

Authors:  Magdalena L Circu; Tak Yee Aw
Journal:  Free Radic Res       Date:  2011-09-05

Review 3.  Cystic fibrosis: an inherited disease affecting mucin-producing organs.

Authors:  Camille Ehre; Caroline Ridley; David J Thornton
Journal:  Int J Biochem Cell Biol       Date:  2014-03-28       Impact factor: 5.085

Review 4.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

Review 5.  Recent advances in small bowel diseases: Part II.

Authors:  Alan B R Thomson; Angeli Chopra; Michael Tom Clandinin; Hugh Freeman
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 6.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

7.  Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.

Authors:  Susan V Lynch; Katherine C Goldfarb; Yvette K Wild; Weidong Kong; Robert C De Lisle; Eoin L Brodie
Journal:  Gut Microbes       Date:  2012-10-12

8.  Defective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.

Authors:  Jinghua Liu; Nancy M Walker; Akifumi Ootani; Ashlee M Strubberg; Lane L Clarke
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

9.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

Review 10.  Intestinal goblet cells and mucins in health and disease: recent insights and progress.

Authors:  Young S Kim; Samuel B Ho
Journal:  Curr Gastroenterol Rep       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.